PDCD1 and neoplasm: Preclinical data demonstrates that anti-LAG-3 is mildly effective as monotherapy, but potently synergizes with anti-PD-1, suggesting that the combined immune checkpoint inhibition could enhance T cell activity and improve anti-tumor immunity [32].